Continuous infusion of escalated doses of Amphotericin B deoxycholate: An open-label observational study

Clinical Infectious Diseases

Volumn 36, Issue 8, 2003, Pages 943-951

  Imhof, Alexander ^a,b   Walter, Roland B ^a,b   Schaffner, Andreas ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; BICARBONATE; BILIRUBIN; C REACTIVE PROTEIN; CREATINE; CYCLOSPORIN; DIURETIC AGENT; GLYCOPEPTIDE; MAGNESIUM; POTASSIUM; AMPHOTERICIN B; AMPHOTERICIN B-DEOXYCHOLATE; DEOXYCHOLIC ACID; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FEMALE; FEVER; HUMAN; IMMUNE DEFICIENCY; KIDNEY FUNCTION; LIVER TOXICITY; MALE; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPEN STUDY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PRURITUS; RESPIRATORY DISTRESS; RIGOR; VOMITING; ADOLESCENT; COHORT ANALYSIS; DRUG COMBINATION; INFUSION PUMP; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; COHORT STUDIES; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFUSION PUMPS; MALE; MIDDLE AGED; MYCOSES; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; TREATMENT OUTCOME;

EID: 0037445546     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/368312     Document Type: Article

References (31)

1. Richardson MD, Kokki MH. Diagnosis and prevention of fungal infection in the immunocompromized patient. Blood Rev 1998; 12:241-54.
2. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12:310-50.
3. Richardson MD, Kokki MH. Antifungal therapy in 'bone marrow failure.' Br J Haematol 1998; 100:619-28.
4. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308-29.
5. Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am 1996; 10:365-400.
6. Chabot GG, Pazdur R, Valeriote FA, Baker LH. Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. J Pharm Sci 1989; 78:307-10.
7. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 322:579-82.
8. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001; 45:922-6.
9. Francis P, Lee JW, Hoffman A, et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994; 169:356-68.
10. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764-71.
11. Walsh TJ, Garrett K, Feurerstein E, et al. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother 1995; 39:1065-9.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
13. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
14. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH Jr. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995;20:755-61.
15. Arning M, Scharf RE. Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure. Klin Wochenschr 1989; 67:1020-8.
16. Bernardo JF, Murakami S, Branch RA, Sabra R. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules. Nephron 1995; 70:235-41.
17. Feely J, Heidemann H, Gerkens J, Roberts LJ 2nd, Branch RA. Sodium depletion enhances nephrotoxicity of amphotericin B. Lancet 1981; 1:1422-3.
18. Groll AH, Walsh TJ. Antifungal chemotherapy: advances and perspectives. Swiss Med Wkly 2002; 132:303-11.
19. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antlmicrob Agents Chemother 2001; 45:3487-96.
20. Walsh TJ, Yeldandi V, McEvoy M, et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998; 42:2391-8.
21. Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm Res 1999; 16:1694-701.
22. Pahls S, Schaffner A. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J Infect Dis 1994; 169:1057-61.
23. Leenders AC, de Marie S, ten Kate MT, Bakker-Woudenberg IA, Verbrugh HA. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis. J Antimicrob Chemother 1996; 38:215-25.
24. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995; 38:459-65.
25. Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983; 75:476-81.
26. Furrer K, Schaffner A, Vavricka SR, Halter J, Imhof A, Schanz U. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. Swiss Med Wkly 2002; 132:316-20.
27. Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL. Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 1989; 87:547-52.
28. Miller MA. Reversible hepatotoxicity related to amphotericin B. Can Med Assoc J 1984; 131:1245-7.
29. Gill J, Sprenger HR, Ralph ED, Sharpe MD. Hepatotoxicity possibly caused by amphotericin B. Ann Pharmacother 1999; 33:683-5.
30. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy: a randomized, controlled trial. Ann Intern Med 2001; 135:412-22.
31. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.